Tumor cell targeting by iron oxide nanoparticles is dominated by different factors in vitro versus in vivo

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  NDong, Christian ^a   Tate, Jennifer A ^a   Kett, Warren C ^a   Batra, Jaya ^a   Demidenko, Eugene ^b   Lewis, Lionel D ^b   Hoopes, P Jack ^b   Gerngross, Tillman U ^a,c,d   Griswold, Karl E ^a,c,d  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Program in Molecular and Cellular Biology ^*  (United States)

^d Lamont Doherty Earth Observatory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IRON OXIDE; IRON OXIDE NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; FERRIC ION; FERRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CANCER CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; TUMOR CELL; TUMOR LOCALIZATION; ZETA POTENTIAL; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; GENETICS; METABOLISM;

ANIMALS; BREAST NEOPLASMS; FERRIC COMPOUNDS; HUMANS; MICE; NANOPARTICLES; RECEPTOR, ERBB-2;

EID: 84923171542     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115636     Document Type: Article

References (50)

1. Na HB, Song IC, Hyeon T (2009) Inorganic Nanoparticles for MRI Contrast Agents. Advanced Materials 21: 2133-2148.
2. Ramchand CN, Priyadarshini P, Kopcansky P, Mehta RV (2001) Applications of magnetic fluids in medicine and biotechnology. Indian Journal of pure and Applied Physics 39: 683-689.
3. Roger J, Pons JN, Massart R, Halbreich A, Bacri JC (1999) Some biomedical applications of ferrofluids. European Physical Journal Applied Physics 5: 321-325.
4. Rosen JE, Chan L, Shieh D-B, Gu FX (2012) Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine: Nanotechnology, Biology and Medicine 8: 275-290. doi: 10.1016/j.nano.2011.08.017 PMID: 21930108
5. Sun C, Lee JS, Zhang M (2008) Magnetic nanoparticles in MR imaging and drug delivery. Advanced Drug Delivery Reviews 60: 1252-1265. doi: 10.1016/j.addr.2008.03.018 PMID: 18558452
6. Varanda LC, Imaizumi M, Santos F, Jafelicci M (2008) Iron Oxide Versus Fe55Pt45/Fe3O4: Improved Magnetic Properties of Core/Shell Nanoparticles for Biomedical Applications. IEEE Transactions on Magnetics 44: 4448-4451.
7. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, et al. (1957) Selective inductive heating of lymph nodes. Annals of Surgery 146: 596-606. PMID: 13470751
8. Hilger I, Hiergeist R, Hergt R, Winnefeld K, Schubert H, et al. (2002) Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study. Investigative Radiology 37: 580-586. PMID: 12352168
9. Johannsen M, Thiesen B, Jordan A, Taymoorian K, Gneveckow U, et al. (2005) Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. Prostate 64: 283-292. PMID: 15726645
10. Jones SK, Winter JG, Gray BN (2002) Treatment of experimental rabbit liver tumours by selectively targeted hyperthermia. International Journal of Hyperthermia 18: 117-128. PMID: 11911482
11. Kievit FM, Zhang M (2011) Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Accounts of Chemical Research 44: 853-862. doi: 10.1021/ar2000277 PMID: 21528865
12. Minamimura T, Sato H, Kasaoka S, Saito T, Ishizawa S, et al. (2000) Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats. International Journal of Oncology 16: 1153-1158. PMID: 10811989
13. Bergey E, Levy L, Wang X, Krebs LJ, Lal M, et al. (2002) DC Magnetic Field Induced Magnetocytolysis of Cancer Cells Targeted by LH-RH Magnetic Nanoparticles in vitro. Biomedical Microdevices 4: 293-299.
14. Jordan A, Scholz R, Wust P, Fahling H, Felix R (1999) Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. Journal of Magnetism and Magnetic Materials 201: 413-419.
15. Prasad N, Rathinasamy K, Panda D, Bahadur D (2007) Mechanism of cell death induced by magnetic hyperthermia with nanoparticles of gamma-MnxFe2-X03 synthesized by a single step process. Journal of Materials Chemistry 17: 5042-5051.
16. Yan S, Zhang D, Gu N, Zheng J, Ding A, et al. (2005) Therapeutic effect of Fe2O3 nanoparticles combined with magnetic fluid hyperthermia on cultured liver cancer cells and xenograft liver cancers. Journal of Nanoscience and Nanotechnology 5: 1185-1192. PMID: 16193975
17. Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, et al. (2010) Magnetic Nanoparticle hyperthermia in cancer treatment. Nano Life 1: 17-32.
18. Moroz P, Jones SK, Gray BN (2002) Magnetically mediated hyperthermia: current status and future directions. International Journal of Hyperthermia 18: 267-284. PMID: 12079583
19. Toraya-Brown S, Sheen MR, Baird JR, Barry S, Demidenko E, et al. (2013) Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. Intergrative Biology 5: 159-171. doi: 10.1039/c2ib20180a PMID: 22935885
20. van der Zee J (2002) Heating the patient: a promising approach? Annals of Oncology 13: 1173-1184. PMID: 12181239
21. Yu MK, Park J, Jon S (2012) Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy. Theranostics 2: 3-44. doi: 10.7150/thno.3463 PMID: 22272217
22. Chen T-J, Cheng T-H, Chen C-Y, Hsu S, Cheng T-L, et al. (2009) Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. Journal of Biological Inorganic Chemistry 14: 253-260. doi: 10.1007/s00775-008-0445-9 PMID: 18975017
23. Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, et al. (2010) EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Research 70: 6303-6312. doi: 10.1158/0008-5472.CAN-10-1022 PMID: 20647323
24. Lu RM, Chang YL, Chen MS, Wu HC (2011) Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32: 3265-3274. doi: 10.1016/j.biomaterials.2010.12.061 PMID: 21306768
25. Yang L, Mao H, Wang YA, Cao Z, Peng X, et al. (2009) Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 5: 235-243. doi: 10.1002/smll.200800714 PMID: 19089838
26. DeNardo SJ, DeNardo GL, Miers LA, Natarajan A, Foreman AR, et al. (2005) Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy. Clinical Cancer Research 11: 7087s-7092s. PMID: 16203807
27. DeNardo SJ, DeNardo GL, Natarajan A, Miers LA, Foreman AR, et al. (2007) Thermal Dosimetry Predictive of Efficacy of 111In-ChL6 Nanoparticle AMF - Induced Thermoablative Therapy for Human Breast Cancer in Mice. Journal of Nuclear Medicine 48: 437-444. PMID: 17332622
28. Kikumori T, Kobayashi T, Sawaki M, Imai T (2009) Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Research and Treatment 113: 435-441. doi: 10.1007/s10549-008-9948-x PMID: 18311580
29. Zhang JP, Dewilde AH, Chinn P, Foreman A, Barry S, et al. (2011) Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill HER-2 positive human breast cells in vitro via hyperthermia. International Journal of Hyperthermia 27: 682-697. doi: 10.3109/02656736.2011.609863 PMID: 21992561
30. Corsi F, Fiandra L, De Palma C, Colombo M, Mazzucchelli S, et al. (2011) HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice. ACS Nano 5: 6383-6393. doi: 10.1021/nn201570n PMID: 21790185
31. Kievit FM, Stephen ZR, Veiseh O, Arami H, Wang T, et al. (2012) Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano 6: 2591-2601. doi: 10.1021/nn205070h PMID: 22324543
32. Fiandra L, Mazzucchelli S, De Palma C, Colombo M, Allevi R, et al. (2013) Assessing the in vivo targeting efficiency of multifunctional nanoconstruct bearing antibody-derived ligands. ACS Nano 7: 6092-6102. doi: 10.1021/nn4018922 PMID: 23758591
33. Nimmerjahn F, Ravetch JV (2007) Antibodies, Fc receptors and cancer. Current Opinion in Immunology 19: 239-245. PMID: 17291742
34. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nature Reviews Immunology 7: 715-725. PMID: 17703228
35. Gong XW, Wei DZ, He ML, Xiong YC (2007) Discarded free PEG-based assay for obtaining the modification extent of pegylated proteins. Talanta 71: 381-384. doi: 10.1016/j.talanta.2006.04.010 PMID: 19071315
36. Hilger I, Kaiser WA (2012) Iron oxide-based nanostructures for MRI and magnetic hyperthermia. Nanomedicine 7: 1443-1459. PMID: 22994960
37. Modi S, Prakash JJ, Domb AJ, Kumar N (2006) Exploiting EPR in polymer drug conjugate delivery for tumor targeting. current Pharmaceutical Design 12: 4785-4796. PMID: 17168778
38. Chen H, Wang L, Yu Q, Qian W, Tiwari D, et al. (2013) Anti-Her2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer International Journal of Nanomedicine 8: 3781-3794. doi: 10.2147/IJN.S49069 PMID: 24124366
39. Douziech-Eyrolles L, Marchais H, Munnier E, Souce M, Linassier C, et al. (2007) Nanovectors for cancer agents based on superparamagnetic iron oxide nanoparticles. International Journal of Nanomedicine 2: 541-550. PMID: 18203422
40. Chithrani BD, Chan WCW (2007) Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Letters 7: 1542-1550. PMID: 17465586
41. Shang L, Nienhaus K, Nienhaus GU (2014) Engineered nanoparticles interacting with cells: size matters Journal of Nanobiotechnology 12.
42. Ito A, Kuga Y, Honda H, Kikkawa H, Horiuchi A, et al. (2004) Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Letters 212: 167-175. PMID: 15279897
43. Hilger I, Dietmar E, Werner L, Strec S, Kaiser WA (2006) Developments for the minimally invasive treatment of tumours by targeted magnetic heating. Journal of Physics: Condensed Matter 18: S2951-S2958.
44. Wahajuddin, Arora S (2012) Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. International Journal of Nanomedicine 7: 3445-3471. doi: 10.2147/IJN.S30320 PMID: 22848170
45. Neuberger T, Schopf B, Hofmann H, Hofmann M, von Rechenberg B (2005) Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. Journal of Magnetism and Magnetic Materials 293: 483-496.
46. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW (2009) Mediating Tumor Targeting Efficiency of Nanoparticles Through Design. Nano Letters 9: 1909-1915. doi: 10.1021/nl900031y PMID: 19344179
47. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P (1996) Development of superparamagnetic nanoparticles for MRI:effect of particle size, charge and surface nature on biodistribution Journal of Microencapsulation 13: 245-255. PMID: 8860681
48. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V (2008) Biodistribution, Clearance and Biocompatibility of Iron Oxide Magnetic Nanoparticles in Rats. Molecular Pharmaceuticals 5: 316-327.
49. Villanueva A, Canete M, Roca AG, Calero M, Veintemillas-Verdaguer S, et al. (2009) The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells. Nanotechnology 20: 115103. doi: 10.1088/0957-4484/20/11/115103 PMID: 19420433
50. Liu D, Wu W, Ling J, Wen S, Gu N, et al. (2011) Effective PEGylation of iron oxide nanoparticles for high performance in vivo cancer imaging. Advanced Functional Materials 21: 1498-1504.